Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT ID: NCT00212628
Last Updated: 2012-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
444 participants
INTERVENTIONAL
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00212667
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00212719
ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
NCT00794443
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
NCT02156960
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minodronic acid hydrate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients having secondary osteoporosis or another condition that presents low bone mass
55 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Project Leader, Development Planning
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chugoku Region Facility
Chugoku, , Japan
Chubu Region Facility
Chūbu, , Japan
Hokkaido Region Facility
Hokkaido, , Japan
Hokuriku Region Facility
Hokuriku, , Japan
Kanto Region Facility
Kanto, , Japan
Kinki Region Facility
Kinki, , Japan
Kyushu Region Facility
Kyushu, , Japan
Shikoku Region Facility
Shikoku Region Facility, , Japan
Tohoku Region Facility
Tōhoku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-5920-04
Identifier Type: -
Identifier Source: org_study_id
NCT00189865
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.